They said my calcium was up

Gordon is a reserved, semi-retired joiner. When asked an open question he says he feels reasonably well, but he does not conceal information after a relevant question. Reveal the following details progressively. Do not volunteer a diagnostic symptom list in the opening sentence. Accept natural questions rather than demanding a particular phrase.

His two central questions are whether this means myeloma and whether stopping his water tablet would be enough. Later he asks whether he really needs a neck operation. Allow the candidate to discover these concerns; do not reward a long explanation that never checks what matters to him.

For about a year he has been more thirsty, keeps water at his bedside and in his van, and estimates drinking roughly twice his previous amount. He wakes to pass urine three times a night. Clarify actual intake and urine volume rather than turning this estimate into a measured fluid balance.

Bowels now open every three to four days with straining; he takes senna most nights. There is no rectal bleeding or current abdominal pain. For 18 months he has felt tired, falls asleep after tea and describes a flat mood. No suicidal thoughts. He made two measuring mistakes at work over six months and is less confident with complex jobs.

There are intermittent, vague leg and back aches, but no persistent focal spinal pain, night pain, focal weakness or known fragility fracture. Symptoms are not specific to high calcium: record their impact without promising that correcting calcium will resolve every complaint.

Two years ago he had severe left loin-to-groin pain, attended emergency care and passed a stone at home. He recalls no metabolic follow-up. Ask about recurrent pain, urinary infection and haematuria; none is present now. Seek the previous records rather than assuming the stone composition is known.

No vomiting, inability to drink, confusion, collapse, palpitations or seizures. Appetite and weight are stable. No fever, night sweats, persistent cough, haemoptysis, neck lump, voice change or focal bone pain. These negatives reduce concern for some alternatives but do not exclude cancer.

No prolonged immobilisation, known malignancy, granulomatous disease or advanced kidney disease. Hypertension since 2014 and reflux are his principal background conditions. Right inguinal hernia repair in 2003 was uncomplicated.

Bendroflumethiazide 2.5 mg each morning; amlodipine 5 mg daily; lansoprazole 15 mg daily. He bought colecalciferol 4,000 units daily six months ago for tiredness. Senna 7.5 mg, one or two tablets on most nights; occasional paracetamol. No known allergies.

Specifically ask about lithium, calcium-containing antacids, other supplements and vitamin A: he takes none. Establish when the thiazide began and obtain prescribing records; the draft does not establish that hypercalcaemia preceded it. A historical high calcium cannot by itself disprove a longstanding drug effect.

No known family history of hypercalcaemia, parathyroid disease or recurrent renal stones. His brother and two adult daughters are well, but their calcium results are unknown. A negative reported family history does not rule out an inherited disorder.

He lives with Christine, 64, and works three days a week without paid sick leave. He is independent and gardens. Former smoker, approximately 10 pack-years, stopped at 40; alcohol about eight units weekly. Ordinary diet without excessive dairy intake.

A colleague had myeloma, so the internet search has frightened him. His brother-in-law had persistent voice problems after thyroid surgery. He worries about losing his voice and income, not simply the size of a scar. If asked what he hopes for, he says: 'Stop the water tablet, repeat the blood test, and forget about it.'

Pulse 74/min, BP 148/86 mmHg, respiratory rate 14/min, oxygen saturation 98% on air, temperature 36.5°C, alert. Weight 82 kg, height 1.75 m, BMI 26.8; weight unchanged over 14 months. Capillary glucose 5.1 mmol/L. NEWS2 is 0 using standard scale 1, but this does not measure the severity of a calcium disorder.

Ask permission and assess cognition, oral intake and hydration first. Confusion, haemodynamic compromise, inability to drink or significant dehydration would interrupt the rehearsal and prompt urgent treatment. Current stability permits a focused encounter while arranging appropriate specialist advice.

Mucous membranes are slightly dry. Supine BP 148/86 becomes 144/84 on standing without dizziness. He is oriented and follows the conversation appropriately; a formal brief cognitive screen, if indicated and performed, is normal. Mild dryness supports reassessing intake, but isolated skin turgor in an older adult is not a precise measure of fluid deficit.

He rises from a chair without using his arms and has full proximal power. This does not make the fatigue unreal or exclude a metabolic contribution. Ask about daily function and mood alongside the physical examination rather than inventing weakness to make the case more obvious.

With appropriate exposure, examine the neck and lymph nodes, chest and abdomen. No palpable neck mass or lymphadenopathy, normal voice, clear lungs, normal heart sounds, no oedema, abdominal mass or organomegaly. There is no focal spinal or rib tenderness. A parathyroid adenoma is usually not palpable; a normal neck examination does not exclude it.

Select additional examination from symptoms and findings. An intimate examination is not a compulsory checklist item in this 15-minute male consultation: explain its indication, obtain consent and offer appropriate chaperoning if needed. Do not claim to have excluded malignancy from a normal examination or undertake painful, indiscriminate bone percussion.

Albumin-adjusted calcium today 2.92 mmol/L (reference 2.20–2.60); four and eight weeks earlier 2.88; a retrieved result three years earlier was 2.71. Albumin 41 g/L. Concurrent PTH 8.4 pmol/L (1.6–6.9), phosphate 0.68 mmol/L (0.80–1.50), magnesium 0.82 mmol/L.

Sodium 140, potassium 4.0, urea 7.2 mmol/L; creatinine 108 micromol/L, reported eGFR 62 mL/min/1.73 m². ALP 132 U/L (30–130), bilirubin 11 micromol/L, ALT 28 U/L. The PTH should be suppressed in response to raised calcium; this is a PTH-dependent pattern. Low phosphate is compatible with PTH-mediated renal phosphate loss, not a diagnostic test on its own.

A single eGFR does not establish chronic kidney disease or prove calcium caused renal impairment. Review prior kidney function and repeat after addressing hydration. There is no history of prolonged severe renal disease to make tertiary hyperparathyroidism the leading explanation.

If the candidate requests relevant completed tests: haemoglobin 141 g/L, WBC 6.8 and platelets 244 × 10⁹/L; ESR 12 mm/hour, CRP 3 mg/L. Serum electrophoresis shows no paraprotein and free light-chain ratio is within the laboratory range. TSH 2.1 mIU/L, free T4 14.8 pmol/L, 25-hydroxyvitamin D 78 nmol/L. ECG shows sinus rhythm, QTc 392 ms; chest radiograph is unremarkable.

These results are reassuring in context, not universal exclusions. Neither a normal chest radiograph nor normal protein tests rules out every malignancy. Vitamin D is replete, with no biochemical evidence here of intoxication; the dose alone does not establish toxicity. Tests for adrenal or granulomatous disease should follow clinical suspicion rather than be presented as compulsory screening already proven negative.

No valid off-thiazide urine study is available at the initial encounter. Arrange urine calcium assessment with endocrinology to help distinguish familial hypocalciuric hypercalcaemia (FHH) from primary hyperparathyroidism before an operative decision.

Delayed teaching result: after the clinician withholds the thiazide for at least one week and organises paired blood and a complete 24-hour urine collection, the laboratory reports a calcium:creatinine clearance ratio of 0.021. This is less suggestive of FHH but does not independently exclude it. Interpret with renal function, vitamin D, collection quality, earlier results and family history. The ESE consensus describes overlap and warns that thiazides lower this ratio; a lab comment is not a substitute for those checks.

DXA and renal ultrasound have not yet been performed. Arrange bone-density assessment at lumbar spine, hip and distal radius, plus renal-tract ultrasound and renal-function review. The forearm matters because cortical bone loss may not be captured adequately by spine and hip alone.

Parathyroid localisation is not the diagnostic test. Ultrasound and, when useful, sestamibi imaging inform the surgical approach once surgery is being considered. Negative localisation does not negate a biochemical diagnosis or automatically prevent surgery; specialist exploration may still be appropriate.

Start with his agenda and permission: 'I'd like to understand how you have been, examine you and then go through what the result might mean. What has worried you most?' Spend approximately six minutes on focused history, three on a directed examination and six discussing results and a negotiated plan. These are rehearsal allocations, not official sub-timers.

Use direct questions after the opening narrative: thirst, urine frequency, constipation, mood, concentration, stones and fractures. Explain why apparently unrelated questions matter. Summarise back the effect on work and sleep. Do not tell him that feeling well was dishonest or that all his symptoms must have one cause.

'Gordon is 66 with repeatedly raised adjusted calcium, currently 2.92, and an inappropriately raised concurrent PTH. He describes chronic thirst, nocturia and constipation, with fatigue and a previous renal stone. He is stable but mildly dry. Primary hyperparathyroidism is the leading working diagnosis; medication contribution and FHH still need assessment.'

Primary hyperparathyroidism fits the PTH pattern, chronicity and stone history. Thiazide-associated hypercalcaemia remains a genuine competing or contributing explanation; it can unmask underlying disease. FHH can also have normal or raised PTH. Do not treat a modest PTH elevation as proof of a solitary adenoma.

Malignancy-associated hypercalcaemia usually suppresses PTH, so it is less likely as the unifying explanation here. Longstanding mild elevation and the current negative findings support that assessment, but do not exclude coexisting cancer. Vitamin D excess, granulomatous disease and thyrotoxicosis usually belong to the suppressed-PTH branch; pursue them if the evolving evidence warrants it.

Because he is symptomatic and mildly dehydrated, discuss him with the senior clinician/endocrine or acute team today to determine whether same-day treatment or supervised outpatient investigation is safest. Do not label referral 'routine only' because calcium is below 3.0. CKS advises considering same-day referral or specialist liaison in symptomatic patients; the clinical picture, trend and ability to maintain fluids determine disposition.

Review and withhold bendroflumethiazide with a documented alternative blood-pressure plan and monitoring. Review the unnecessary self-prescribed 4,000-unit vitamin D supplement and stop that high-dose self-treatment pending the clinician's plan. This is not a permanent prohibition on vitamin D: documented deficiency in probable primary hyperparathyroidism should be corrected with monitoring.

Encourage regular oral fluids if he can drink and has no fluid restriction, with an individual target agreed after cardiac/renal assessment. Do not give a universal forced-volume prescription. Arrange an early calcium/renal-function and BP review under the agreed plan; worsening symptoms require review sooner. A three-week test used to assess a thiazide effect is not permission to leave this symptomatic man unassessed until then.

Complete specialist diagnostic assessment, including consideration of FHH. For confirmed primary hyperparathyroidism, NICE surgical referral criteria are alternatives: hypercalcaemic symptoms, renal stones/fragility fracture/osteoporosis, or adjusted calcium at least 2.85 mmol/L. His calcium and stone history already support referral even if he had no symptoms. A better history changes the conversation and symptom assessment, but is not what uniquely makes him eligible.

'I recommend discussing treatment with a parathyroid surgeon once we have confirmed the cause. That appointment is not a commitment to an operation. The blood level and previous stone already give reasons to discuss it, and the symptoms you describe may also be relevant. We should not assume that changing one tablet has settled the problem.'

'I can see why your colleague's experience has worried you. One of the results is a hormone that normally switches down when calcium rises. Yours is still raised, which points more towards the small parathyroid glands than towards cancer causing the calcium result. The other tests are reassuring too. That makes myeloma less likely, but I cannot use these results to promise that every cancer is excluded.'

'Our next tests are to confirm the cause and see whether the bones or kidneys have been affected. If you develop persistent focal bone pain, weight loss or other new symptoms, tell us so we can reassess.' Avoid the draft's claim that myeloma cannot remain quiet for three years. Also avoid saying that the tablet cannot be involved simply because an old calcium result was high.

Explain that one or more overactive glands may be responsible; localisation may help select a focused operation or wider exploration. Discuss the possibility of cure alongside anaesthetic risks, bleeding, infection, scarring, voice injury, low postoperative calcium and persistent disease. The surgeon should explain individual and local outcome risks; do not import a relative's outcome or a hospital's percentages as Gordon's personal risk.

'The nerve near these glands helps control the voice. Voice changes are a real risk and can occasionally persist. I won't dismiss what happened to your brother-in-law. Your operation may be different, but we need the surgeon to explain your particular options and risks.' Do not guarantee a smaller scar, easier recovery or improvement in every nonspecific symptom.

Ask what work he cannot afford to miss and whether lighter duties are possible. Request a realistic recovery discussion with the surgical team, written information and, with consent, Christine's involvement. Allow time to decide and offer a follow-up conversation. Informed refusal is not incapacity.

NICE allows consideration of cinacalcet when surgery is unsuccessful, unsuitable or declined and calcium is at least 2.85 with symptoms, or at least 3.0 with or without symptoms. Discuss this with endocrinology rather than issue an unmonitored prescription. It can lower calcium but does not remove the underlying gland disorder. Assess benefit and adverse effects; monitoring must follow the current product information, not merely annual blood tests.

For stable non-operated disease without cinacalcet, NICE specifies annual calcium and renal-function monitoring, consideration of DXA every two to three years and renal imaging when stones are suspected after baseline assessment. These long-term intervals do not replace early reassessment after medication changes or new symptoms. Assess fracture and cardiovascular risk. A bisphosphonate may be appropriate for fracture prevention, but not as routine treatment for chronic hypercalcaemia of primary hyperparathyroidism.

Write down who is arranging endocrine advice, the medicine change, repeat blood tests, DXA and ultrasound, and when Gordon should expect contact. If the referral has not arrived within the agreed local interval, he should contact the named clinic/GP rather than wait indefinitely. Do not promise a fixed national surgical waiting time.

New confusion, marked drowsiness, collapse or severe illness requires emergency assessment; call 999 if severely unwell or transport is unsafe. Persistent vomiting or inability to maintain fluids requires urgent same-day assessment. New renal-colic pain, particularly with fever or reduced urine, also needs urgent assessment. Do not tell a confused patient merely to book a routine GP visit.

Ask: 'What will you tell Christine about the likely cause and our next steps? Which tablets are changing, and what would make you seek help today?' The desired response is a likely parathyroid problem requiring further assessment, not a guaranteed benign diagnosis or a guaranteed operation.

Reclassify as PTH-independent hypercalcaemia and investigate accordingly. Malignancy, vitamin D-related and granulomatous causes now move up the differential. Reassess symptoms, medicines and examination; choose further blood tests and imaging from that evidence. Highlight hypercalcaemia in any suspected-cancer referral.

Do not assert cancer from the PTH result alone, or continue towards parathyroid surgery on the original assumption. A normal chest radiograph does not settle the cause. Hydration, severity assessment and prompt specialist input remain important regardless of the branch.

This is an endocrine emergency. Arrange emergency admission, ABCDE assessment, ECG monitoring, IV access and urgent calcium/renal/electrolyte assessment with senior endocrine involvement. Treat volume depletion with IV 0.9% sodium chloride, individualising rate and volume to cardiovascular and renal status; monitor fluid balance and overload.

After rehydration, if further calcium lowering is needed, specialist treatment may include IV bisphosphonate with renal precautions; response is delayed over days, not minutes. Do not blindly give a fixed multi-litre regimen or use routine loop diuretics to lower calcium. Review contributing medicines and determine the cause; severe refractory primary hyperparathyroidism may need urgent surgical discussion. The stable outpatient plan no longer applies.

FHH becomes more plausible, not proven. Check collection quality, medication exposure, renal function and vitamin D before interpreting the urine result. Arrange specialist review of historical/family biochemistry and possible genetic assessment. Explain that a negative genetic test may not resolve every uncertain case.

Pause the operative decision rather than send him directly to surgery or declare lifelong benign disease from one test. If FHH is confirmed, routine parathyroidectomy is generally inappropriate. The new family information changes the working diagnosis; it does not mean the earlier concern was unreasonable.

Check understanding and practical barriers without coercion. He can decline even when referral is well supported. Agree an endocrine-led plan, including whether cinacalcet fits his symptoms/calcium and what monitoring it requires. Discuss bone protection separately, and arrange baseline end-organ assessment and surveillance.

Keep the option of surgery open for later discussion, especially if stones, fractures, renal function or symptoms change. Do not portray monitoring as doing nothing, or promise it gives the same outcome as surgery. Record his priorities and the review owner.

Strong: Elicits specific symptoms, functional effect, OTC medicines, stone history and both cancer and voice concerns.

Incomplete: Accepts 'I feel fine' without exploring thirst, urine, bowels or work.

Unsafe: Dismisses deterioration symptoms or offers categorical reassurance that cancer is excluded.

Strong: Assesses hydration and cognition first; reports the supplied normal findings honestly and explains their limits.

Incomplete: Examines only the neck and treats its normality as sufficient.

Unsafe: Invents a mass or performs an intimate examination without consent.

Strong: Uses paired calcium/PTH, acknowledges medication confounding and investigates possible FHH before an operative decision.

Incomplete: Names primary hyperparathyroidism but cannot explain alternatives or urine-test limitations.

Unsafe: Treats a single urine ratio as definitive or closes the case after stopping the thiazide.

Strong: Seeks prompt specialist advice for this symptomatic man and separates stable care from an acute calcium emergency.

Incomplete: Lists tests without timing, medication ownership or follow-up.

Unsafe: Calls symptomatic dehydration routine-only, delays emergency treatment, or prescribes a fixed large fluid load without reassessment.

Strong: Explains referral criteria accurately, discusses voice and calcium risks, respects refusal and makes monitoring specific.

Incomplete: Recommends surgery but does not address income, voice fears or alternatives.

Unsafe: Pressures consent, guarantees cure of all symptoms, or uses annual checks alone for newly started cinacalcet.